# A First-In-Human Study of ARO-INHBE in Adults With Obesity With and Without Type 2 Diabetes Mellitus

> **NCT06700538** · PHASE1,PHASE2 · RECRUITING · sponsor: **Arrowhead Pharmaceuticals** · enrollment: 180 (estimated)

## Conditions studied

- Obesity

## Interventions

- **DRUG:** ARO-INHBE
- **DRUG:** Placebo
- **DRUG:** Tirzepatide

## Key facts

- **NCT ID:** NCT06700538
- **Lead sponsor:** Arrowhead Pharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2024-12-04
- **Primary completion:** 2027-09-17
- **Final completion:** 2028-01-17
- **Target enrollment:** 180 (ESTIMATED)
- **Last updated:** 2026-04-24


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06700538

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06700538, "A First-In-Human Study of ARO-INHBE in Adults With Obesity With and Without Type 2 Diabetes Mellitus". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT06700538. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*